PD-1/PD-L1 blockade immunotherapy has recently joined chemotherapy as a standard treatment for lung and several other cancers (Doroshow et al., 2019; Zou et al., 2016; Zappasodi et al., 2018). This evidence concerns the gene PDCD1 and cancer.